HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · IEX Real-Time Price · USD
18.56
+0.55 (3.05%)
At close: Jul 26, 2024, 4:00 PM
18.00
-0.56 (-3.02%)
After-hours: Jul 26, 2024, 7:16 PM EDT
HUTCHMED (China) Revenue
In the year 2023, HUTCHMED (China) had annual revenue of $838.00M with 96.52% growth. HUTCHMED (China) had revenue of $305.13M in the half year ending December 31, 2023, with 53.51% growth.
Revenue (ttm)
$838.00M
Revenue Growth
+96.52%
P/S Ratio
3.86
Revenue / Employee
$421,529
Employees
1,988
Market Cap
3.23B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
Dec 31, 2019 | 204.89M | -9.22M | -4.31% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Oscar Health | 6.54B |
ICU Medical | 2.26B |
Amedisys | 2.25B |
ACADIA Pharmaceuticals | 813.81M |
GoodRx Holdings | 764.16M |
Azenta | 651.76M |
Inari Medical | 520.66M |
Amicus Therapeutics | 423.49M |
HCM News
- 23 days ago - HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status - GlobeNewsWire
- 4 weeks ago - HUTCHMED to Announce 2024 Half-Year Financial Results - GlobeNewsWire
- 4 weeks ago - Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 - GlobeNewsWire
- 5 weeks ago - HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda - GlobeNewsWire
- 5 weeks ago - HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology - GlobeNewsWire
- 7 weeks ago - HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China - GlobeNewsWire
- 7 weeks ago - HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine - GlobeNewsWire
- 2 months ago - HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting - GlobeNewsWire